PMID- 29685478
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20200420
IS  - 1532-1983 (Electronic)
IS  - 0261-5614 (Linking)
VI  - 38
IP  - 2
DP  - 2019 Apr
TI  - Postprandial endotoxemia may influence the development of type 2 diabetes 
      mellitus: From the CORDIOPREV study.
PG  - 529-538
LID - S0261-5614(18)30128-6 [pii]
LID - 10.1016/j.clnu.2018.03.016 [doi]
AB  - BACKGROUND & AIMS: Insulin resistance (IR) and impaired beta-cell function are 
      key determinants of type 2 diabetes mellitus (T2DM). Intestinal absorption of 
      bacterial components activates the toll-like receptors inducing inflammation, and 
      this in turn IR. We evaluated the role of endotoxemia in promoting 
      inflammation-induced insulin resistance (IR) in the development of T2DM, and its 
      usefulness as predictive biomarker. METHODS: We included in this study 462 
      patients from the CORDIOPREV study without T2DM at baseline. Of these, 107 
      patients developed T2DM according to the American Diabetes Association (ADA) 
      diagnosis criteria after a median follow-up of 60 months (Incident-DIAB group), 
      whereas 355 patients did not developed it during this period of time (Non-DIAB 
      group). RESULTS: We observed a postprandial increase in lipopolysaccharides (LPS) 
      levels in the Incident-DIAB at baseline (P < 0.001), whereas LPS levels were not 
      modified in the Non-DIAB. Disease-free survival curves based on the LPS 
      postprandial fold change improved T2DM Risk Assessment as compared with the 
      previously described FINDRISC score (hazard ratio of 2.076, 95% CI 1.149-3.750 
      vs. 1.384, 95% CI 0.740-2.589). Moreover, disease-free survival curves combining 
      the LPS postprandial fold change and FINDRISC score together showed a hazard 
      ratio of 3.835 (95% CI 1.323-11.114), linked to high values of both parameters. 
      CONCLUSION: Our results suggest that a high postprandial endotoxemia precedes the 
      development of T2DM. Our results also showed the potential use of LPS plasma 
      levels as a biomarker predictor of T2DM development. CLINICAL TRIALS.GOV. 
      IDENTIFIER: NCT00924937.
CI  - Copyright (c) 2018 Elsevier Ltd and European Society for Clinical Nutrition and 
      Metabolism. All rights reserved.
FAU - Camargo, Antonio
AU  - Camargo A
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - Jimenez-Lucena, Rosa
AU  - Jimenez-Lucena R
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - Alcala-Diaz, Juan F
AU  - Alcala-Diaz JF
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - Rangel-Zuniga, Oriol A
AU  - Rangel-Zuniga OA
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - Garcia-Carpintero, Sonia
AU  - Garcia-Carpintero S
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - Lopez-Moreno, Javier
AU  - Lopez-Moreno J
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - Blanco-Rojo, Ruth
AU  - Blanco-Rojo R
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - Delgado-Lista, Javier
AU  - Delgado-Lista J
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - Perez-Martinez, Pablo
AU  - Perez-Martinez P
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - van Ommen, Ben
AU  - van Ommen B
AD  - Netherlands Institute for Applied Science (TNO), Research Group Microbiology & 
      Systems Biology, Zeist, The Netherlands.
FAU - Malagon, Maria M
AU  - Malagon MM
AD  - CIBER Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud 
      Carlos III, Cordoba, Spain; Department of Cell Biology, Physiology and 
      Immunology, University of Cordoba, Cordoba, Spain.
FAU - Ordovas, Jose M
AU  - Ordovas JM
AD  - Nutrition and Genomics Laboratory, J.M.-US Department of Agriculture Human 
      Nutrition Research Center on Aging at Tufts University, Boston, MA, USA; IMDEA 
      Alimentacion, Madrid, Spain; CNIC, Madrid, Spain.
FAU - Perez-Jimenez, Francisco
AU  - Perez-Jimenez F
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
FAU - Lopez-Miranda, Jose
AU  - Lopez-Miranda J
AD  - Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical 
      Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, 
      University of Cordoba, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion 
      (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain. Electronic address: 
      jlopezmir@uco.es.
LA  - eng
SI  - ClinicalTrials.gov/NCT00924937
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180411
PL  - England
TA  - Clin Nutr
JT  - Clinical nutrition (Edinburgh, Scotland)
JID - 8309603
SB  - IM
MH  - Diabetes Mellitus, Type 2/*complications/physiopathology
MH  - Endotoxemia/*complications/physiopathology
MH  - Female
MH  - Humans
MH  - Hyperlipidemias/complications/physiopathology
MH  - Insulin Resistance/physiology
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period/*physiology
OTO - NOTNLM
OT  - CORDIOPREV
OT  - Diabetes
OT  - Endotoxemia
OT  - Inflammation
OT  - Prediction model
EDAT- 2018/04/25 06:00
MHDA- 2020/04/21 06:00
CRDT- 2018/04/25 06:00
PHST- 2017/12/20 00:00 [received]
PHST- 2018/03/08 00:00 [revised]
PHST- 2018/03/28 00:00 [accepted]
PHST- 2018/04/25 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
PHST- 2018/04/25 06:00 [entrez]
AID - S0261-5614(18)30128-6 [pii]
AID - 10.1016/j.clnu.2018.03.016 [doi]
PST - ppublish
SO  - Clin Nutr. 2019 Apr;38(2):529-538. doi: 10.1016/j.clnu.2018.03.016. Epub 2018 Apr 
      11.